BioAge Labs, Inc. BIOA
7.05
(0.16)
(2.22%)
as of 25 Sep
- Market cap
- $337.4M
- P/E
- 0.0×
Follow BIOA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (28.21%) | (25.98%) | (27.09%) | (25.64%) |
+7 more TTM periods Free account |
|
| (26.27%) | (24.26%) | (24.68%) | (23.59%) | ||
ROIC |
(118.25%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(30.25%) | (23.84%) | (30.12%) | (28.35%) | |
Average Days of Receivables |
22.03 | 25.09 | 31.20 | 0.00 | |
Free Cash Flow per Share |
(5.42) | (5.73) | (6.60) | (1.65) | |
Free Cash Flow |
(242.84) | (243.38) | (237.09) | (59.15) | |
Capital Expenditures |
(155.23) | (155.07) | (155.47) | (0.63) | |
Piotroski F-Score |
1.00 | 1.00 | 0.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(12.63%) | (11.57%) | (14.69%) | (10.31%) | |
Accounts Receivable Turnover |
16.86 | 19.28 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
847.78% | 807.16% | 822.30% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
278.49% | 278.77% | 309.16% | 0.00% | |
Share Based Compensation of Revenue |
135.57% | 126.00% | 129.97% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.93 | 0.98 | 1.01 | 0.77 | |
Depreciation/Fixed assets |
0.21 | 0.21 | 0.22 | 0.20 | |
Capex/Depreciation |
(618.47) | (648.81) | (729.89) | (3.31) | |
Revenue per Share |
0.23 | 0.24 | 0.25 | 0.00 | |
Operating CF per Share |
(1.95) | (2.08) | (2.27) | (1.63) | |
Capex per Share |
(3.46) | (3.65) | (4.33) | (0.02) | |
Capex to Sales |
14.99 | 15.03 | 17.28 | 0.00 | |
Net Profit Margin |
(912.25%) | (871.75%) | (896.11%) | 0.00% |
Columns are period end dates